NOV 22, 2016 10:04 AM PST

Brain Tumors All Aglow

WRITTEN BY: Xuan Pham
In as much as 50 percent of operations to remove brain tumors, some cancerous bits are left behind and the cancer makes a most unwelcomed return. Now, researchers at the University of Pennsylvania say a technique that makes brain tumors fluoresce during surgery will enable more thorough removal and minimize tumor recurrence.


 
Each year, surgeons operate on over 15,000 patients to remove brain tumors. The extremely delicate nature of these operations already put patients at increased risks for complications. Furthermore, the success of the operation is drastically minimized when tumor tissues are left behind because the tumor margins are difficult to identify.
 
To circumvent cancer’s ability to camouflage itself among normal tissues, Penn researchers set out to make cancer as visible as possible to the surgeon. Specifically, they engineered a dye that collects mostly in the tumor tissues, making the cancer glow brightly as compared to the healthy tissues.
 
The dye agent is known as indocyanine green (ICG), and it is visualized with near infrared imaging light. "Fluorescent contrast agents take visualization to a whole new level," said John Lee, associate professor at the University of Pennsylvania’s School of Medicine. "It has the potential for real-time imaging, identification of disease, and most importantly, precise detection of the tumor's margins. With this, we know better where to cut."
 
The concept of making tumors glow is not new. Last month, doctors from Seattle Children’s Hospital used a chemical called BLZ-100 Tumor Paint to aid in the removal of a brain tumor in a 2-year-old. Of note, both techniques employ the use of the dye, indocyanine green.
 

In the current pilot study at Penn, researchers say their technique showed successful visual enhancement in 12 out of 15 tumors. Of those patients in which the fluorescence signal was strong, surgeons reported the glow was visible even under the dura.
 
"This technique, if approved by the FDA, may offer great promise to physicians and patients," Singhal said. "It's a strategy that could allow greater precision across many different cancer types, help with early detection, and hopefully better treatment success."
 
Additional sources: Perelman School of Medicine at the University of Pennsylvania
About the Author
Bachelor's (BA/BS/Other)
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 04, 2022
Cancer
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
In August, President Biden announced his intention to appoint Dr. Monica M. Bertagnolli as the newest director of the Na ...
OCT 12, 2022
Plants & Animals
Mediterranean Diet Improves Immunotherapy Response in Advanced Melanoma Patients
Mediterranean Diet Improves Immunotherapy Response in Advanced Melanoma Patients
The Mediterranean diet has been popularized in recent years for its wide-ranging health benefits. Among the many health ...
OCT 25, 2022
Cancer
Study Identifies Patients at High Risk of Breast Cancer Metastasis
Study Identifies Patients at High Risk of Breast Cancer Metastasis
Central nervous system metastasis (mCNS) accounts for most brain and spinal cord tumors.  While recent advances hav ...
OCT 28, 2022
Cancer
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive type of pancreatic cancer, has a very poor prognosis due, a ...
NOV 22, 2022
Clinical & Molecular DX
Women With Benign Breast Diseases, Including Cysts and Fibroadenomas, Face Higher Risk of Breast Cancer
Women With Benign Breast Diseases, Including Cysts and Fibroadenomas, Face Higher Risk of Breast Cancer
Though they are very common, benign breast diseases may indicate an increased likelihood of developing breast cancer at ...
NOV 28, 2022
Drug Discovery & Development
Construction of the New US-Based Center for Bioprocessing
Construction of the New US-Based Center for Bioprocessing
Sino Biological is pleased to announce the signing of a lease with Hines and initiation of construction on its new Cente ...
Loading Comments...